Selected research
Market Structure
Global Hepatitis A Inactivated Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Hepatitis A Inactivated Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Hepatitis A Inactivated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Hepatitis A Inactivated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Hepatitis A Inactivated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Hepatitis A Inactivated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Hepatitis A Inactivated Vaccine include Xianghe Pharmaceutical, Sanofi, Merck, Pfizer, GlaxoSmithKline, Limin Pharmaceutical, Huakang Pharmaceutical and Health Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Hepatitis A Inactivated Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Hepatitis A Inactivated Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Hepatitis A Inactivated Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hepatitis A Inactivated Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.
Hepatitis A Inactivated Vaccine Segment by Company
Xianghe Pharmaceutical
Sanofi
Merck
Pfizer
GlaxoSmithKline
Limin Pharmaceutical
Huakang Pharmaceutical
Health Pharma
Hepatitis A Inactivated Vaccine Segment by Type
25U/0.5ml
50U/1.0ml
Hepatitis A Inactivated Vaccine Segment by Application
Hospital
Clinic
Others
Hepatitis A Inactivated Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis A Inactivated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hepatitis A Inactivated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis A Inactivated Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Hepatitis A Inactivated Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hepatitis A Inactivated Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hepatitis A Inactivated Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Hepatitis A Inactivated Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 25U/0.5ml
- 50U/1.0ml
Applications
- Hospital
- Clinic
- Others
Companies covered
- Xianghe Pharmaceutical
- Sanofi
- Merck
- Pfizer
- GlaxoSmithKline
- Limin Pharmaceutical
- Huakang Pharmaceutical
- Health Pharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Hepatitis A Inactivated Vaccine Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Hepatitis A Inactivated Vaccine Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Hepatitis A Inactivated Vaccine Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Hepatitis A Inactivated Vaccine Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Hepatitis A Inactivated Vaccine Market Dynamics
- 2.1 Hepatitis A Inactivated Vaccine Industry Trends
- 2.2 Hepatitis A Inactivated Vaccine Industry Drivers
- 2.3 Hepatitis A Inactivated Vaccine Industry Opportunities and Challenges
- 2.4 Hepatitis A Inactivated Vaccine Industry Restraints
3 Hepatitis A Inactivated Vaccine Market by Manufacturers
- 3.1 Global Hepatitis A Inactivated Vaccine Revenue by Manufacturers (2021-2026)
- 3.2 Global Hepatitis A Inactivated Vaccine Sales by Manufacturers (2021-2026)
- 3.3 Global Hepatitis A Inactivated Vaccine Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Hepatitis A Inactivated Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Hepatitis A Inactivated Vaccine Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Hepatitis A Inactivated Vaccine Manufacturers, Product Type & Application
- 3.7 Global Hepatitis A Inactivated Vaccine Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Hepatitis A Inactivated Vaccine Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Hepatitis A Inactivated Vaccine Players Market Share by Revenue in 2025
- 3.8.3 2025 Hepatitis A Inactivated Vaccine Tier 1, Tier 2, and Tier 3
4 Hepatitis A Inactivated Vaccine Market by Type
- 4.1 Hepatitis A Inactivated Vaccine Type Introduction
- 4.1.1 25U/0.5ml
- 4.1.2 50U/1.0ml
- 4.2 Global Hepatitis A Inactivated Vaccine Sales by Type
- 4.2.1 Global Hepatitis A Inactivated Vaccine Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Hepatitis A Inactivated Vaccine Sales by Type (2021-2032)
- 4.2.3 Global Hepatitis A Inactivated Vaccine Sales Market Share by Type (2021-2032)
- 4.3 Global Hepatitis A Inactivated Vaccine Revenue by Type
- 4.3.1 Global Hepatitis A Inactivated Vaccine Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Hepatitis A Inactivated Vaccine Revenue by Type (2021-2032)
- 4.3.3 Global Hepatitis A Inactivated Vaccine Revenue Market Share by Type (2021-2032)
5 Hepatitis A Inactivated Vaccine Market by Application
- 5.1 Hepatitis A Inactivated Vaccine Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Hepatitis A Inactivated Vaccine Sales by Application
- 5.2.1 Global Hepatitis A Inactivated Vaccine Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Hepatitis A Inactivated Vaccine Sales by Application (2021-2032)
- 5.2.3 Global Hepatitis A Inactivated Vaccine Sales Market Share by Application (2021-2032)
- 5.3 Global Hepatitis A Inactivated Vaccine Revenue by Application
- 5.3.1 Global Hepatitis A Inactivated Vaccine Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Hepatitis A Inactivated Vaccine Revenue by Application (2021-2032)
- 5.3.3 Global Hepatitis A Inactivated Vaccine Revenue Market Share by Application (2021-2032)
6 Global Hepatitis A Inactivated Vaccine Sales by Region
- 6.1 Global Hepatitis A Inactivated Vaccine Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Hepatitis A Inactivated Vaccine Sales by Region (2021-2032)
- 6.2.1 Global Hepatitis A Inactivated Vaccine Sales by Region (2021-2026)
- 6.2.2 Global Hepatitis A Inactivated Vaccine Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Hepatitis A Inactivated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Hepatitis A Inactivated Vaccine Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Hepatitis A Inactivated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Hepatitis A Inactivated Vaccine Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Hepatitis A Inactivated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Hepatitis A Inactivated Vaccine Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Hepatitis A Inactivated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Hepatitis A Inactivated Vaccine Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Hepatitis A Inactivated Vaccine Revenue by Region
- 7.1 Global Hepatitis A Inactivated Vaccine Revenue by Region
- 7.1.1 Global Hepatitis A Inactivated Vaccine Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Hepatitis A Inactivated Vaccine Revenue by Region (2021-2026)
- 7.1.3 Global Hepatitis A Inactivated Vaccine Revenue by Region (2027-2032)
- 7.1.4 Global Hepatitis A Inactivated Vaccine Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Hepatitis A Inactivated Vaccine Revenue (2021-2032)
- 7.2.2 North America Hepatitis A Inactivated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Hepatitis A Inactivated Vaccine Revenue (2021-2032)
- 7.3.2 Europe Hepatitis A Inactivated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Hepatitis A Inactivated Vaccine Revenue (2021-2032)
- 7.4.2 Asia-Pacific Hepatitis A Inactivated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Hepatitis A Inactivated Vaccine Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Hepatitis A Inactivated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Xianghe Pharmaceutical
- 8.1.1 Xianghe Pharmaceutical Company Information
- 8.1.2 Xianghe Pharmaceutical Business Overview
- 8.1.3 Xianghe Pharmaceutical Hepatitis A Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Xianghe Pharmaceutical Hepatitis A Inactivated Vaccine Product Portfolio
- 8.1.5 Xianghe Pharmaceutical Recent Developments
- 8.2 Sanofi
- 8.2.1 Sanofi Company Information
- 8.2.2 Sanofi Business Overview
- 8.2.3 Sanofi Hepatitis A Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Sanofi Hepatitis A Inactivated Vaccine Product Portfolio
- 8.2.5 Sanofi Recent Developments
- 8.3 Merck
- 8.3.1 Merck Company Information
- 8.3.2 Merck Business Overview
- 8.3.3 Merck Hepatitis A Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Merck Hepatitis A Inactivated Vaccine Product Portfolio
- 8.3.5 Merck Recent Developments
- 8.4 Pfizer
- 8.4.1 Pfizer Company Information
- 8.4.2 Pfizer Business Overview
- 8.4.3 Pfizer Hepatitis A Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Pfizer Hepatitis A Inactivated Vaccine Product Portfolio
- 8.4.5 Pfizer Recent Developments
- 8.5 GlaxoSmithKline
- 8.5.1 GlaxoSmithKline Company Information
- 8.5.2 GlaxoSmithKline Business Overview
- 8.5.3 GlaxoSmithKline Hepatitis A Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 GlaxoSmithKline Hepatitis A Inactivated Vaccine Product Portfolio
- 8.5.5 GlaxoSmithKline Recent Developments
- 8.6 Limin Pharmaceutical
- 8.6.1 Limin Pharmaceutical Company Information
- 8.6.2 Limin Pharmaceutical Business Overview
- 8.6.3 Limin Pharmaceutical Hepatitis A Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Limin Pharmaceutical Hepatitis A Inactivated Vaccine Product Portfolio
- 8.6.5 Limin Pharmaceutical Recent Developments
- 8.7 Huakang Pharmaceutical
- 8.7.1 Huakang Pharmaceutical Company Information
- 8.7.2 Huakang Pharmaceutical Business Overview
- 8.7.3 Huakang Pharmaceutical Hepatitis A Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Huakang Pharmaceutical Hepatitis A Inactivated Vaccine Product Portfolio
- 8.7.5 Huakang Pharmaceutical Recent Developments
- 8.8 Health Pharma
- 8.8.1 Health Pharma Company Information
- 8.8.2 Health Pharma Business Overview
- 8.8.3 Health Pharma Hepatitis A Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Health Pharma Hepatitis A Inactivated Vaccine Product Portfolio
- 8.8.5 Health Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Hepatitis A Inactivated Vaccine Value Chain Analysis
- 9.1.1 Hepatitis A Inactivated Vaccine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Hepatitis A Inactivated Vaccine Production Mode & Process
- 9.2 Hepatitis A Inactivated Vaccine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Hepatitis A Inactivated Vaccine Distributors
- 9.2.3 Hepatitis A Inactivated Vaccine Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst